Financial results for the fiscal year ended March 2026
Japan Tissue Engineering Co.,Ltd. (reporting company)
Regenerative medicine products business (JACE autologous cultured epidermis, JACC autologous cultured cartilage, Nepic autologous cultured corneal epithelium, Ocural autologous cultured oral mucosal epithelium, and JACUMIN melanocyte-containing autologous cultured epidermis), regenerative medicine contract services business, and LabCyte business
In the regenerative medicine products business, the number of eligible patients decreased. In the regenerative medicine contract services business, the achievement of milestones related to Teijin was pushed back to the following fiscal year, and spot revenue from a specific customer recorded in the previous fiscal year fell away. The Company also recorded an impairment loss on investment securities of ¥149.999 million, a loss on disposal of fixed assets of ¥43.332 million and a loss on reduction of fixed asset acquisition costs of ¥31.816 million.
Net sales of ¥2,182.745 million, operating loss of ¥549.445 million, ordinary loss of ¥537.443 million and net loss of ¥734.751 million. Total extraordinary losses were ¥225.148 million, comprising an impairment loss on investment securities of ¥149.999 million, a loss on disposal of fixed assets of ¥43.332 million and a loss on reduction of fixed asset acquisition costs of ¥31.816 million.
Fiscal year ended March 2026 (1 April 2025 to 31 March 2026)
For the fiscal year ending March 2027, the Company forecasts net sales of ¥3,070 million, operating profit of ¥100 million, ordinary profit of ¥110 million and net profit of ¥100 million.
Through sales growth in the regenerative medicine products business, regenerative medicine contract services business and LabCyte business, the Company expects net sales of ¥3,070 million, operating profit of ¥100 million, ordinary profit of ¥110 million and net profit of ¥100 million for the fiscal year ending March 2027.
| Item | Details |
|---|---|
| Event name | Financial results for the fiscal year ended March 2026 |
| Date of occurrence | 31 March 2026 (end of the fiscal year) |
| Subject Entity | Japan Tissue Engineering Co.,Ltd. (reporting company) |
| Target Locations / Products | Regenerative medicine products business (JACE autologous cultured epidermis, JACC autologous cultured cartilage, Nepic autologous cultured corneal epithelium, Ocural autologous cultured oral mucosal epithelium, and JACUMIN melanocyte-containing autologous cultured epidermis), regenerative medicine contract services business, and LabCyte business |
| Cause | In the regenerative medicine products business, the number of eligible patients decreased. In the regenerative medicine contract services business, the achievement of milestones related to Teijin was pushed back to the following fiscal year, and spot revenue from a specific customer recorded in the previous fiscal year fell away. The Company also recorded an impairment loss on investment securities of ¥149.999 million, a loss on disposal of fixed assets of ¥43.332 million and a loss on reduction of fixed asset acquisition costs of ¥31.816 million. |
| Amount of Impact on Business Performance | Net sales of ¥2,182.745 million, operating loss of ¥549.445 million, ordinary loss of ¥537.443 million and net loss of ¥734.751 million. Total extraordinary losses were ¥225.148 million, comprising an impairment loss on investment securities of ¥149.999 million, a loss on disposal of fixed assets of ¥43.332 million and a loss on reduction of fixed asset acquisition costs of ¥31.816 million. |
| Accounting period in which recognized | Fiscal year ended March 2026 (1 April 2025 to 31 March 2026) |
| Impact on Earnings Forecast | For the fiscal year ending March 2027, the Company forecasts net sales of ¥3,070 million, operating profit of ¥100 million, ordinary profit of ¥110 million and net profit of ¥100 million. |
| Outlook | Through sales growth in the regenerative medicine products business, regenerative medicine contract services business and LabCyte business, the Company expects net sales of ¥3,070 million, operating profit of ¥100 million, ordinary profit of ¥110 million and net profit of ¥100 million for the fiscal year ending March 2027. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the regenerative medicine products business, sales declined due to a decrease in the number of eligible patients. In the regenerative medicine contract services business, sales declined because the achievement of milestones related to Teijin was pushed back to the following fiscal year and spot revenue recorded in the previous fiscal year fell away. In addition, the Company recorded an impairment loss on investment securities of ¥149.999 million, a loss on disposal of fixed assets of ¥43.332 million and a loss on reduction of fixed asset acquisition costs of ¥31.816 million.